Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1
- PMID: 8574829
- PMCID: PMC170220
- DOI: 10.1128/cdli.2.6.685-688.1995
Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1
Abstract
Vibrio cholerae serogroup O139, now considered to be the second organism capable of causing epidemic severe dehydrating cholera, contains a capsular polysaccharide which makes it difficult for it to be used in the conventional vibriocidal antibody assay optimized for V. cholerae O1. After modification of the procedure, which involved the use of specific bacterial strains, a lower bacterial inoculum, and increased amounts of complement, the vibriocidal antibody responses to V. cholerae O139 were measured in acute- and convalescent-phase sera from 33 V. cholerae O139-infected and 18 V. cholerae O1-infected patients and in single serum samples from 20 healthy control subjects. The responses in these individuals to V. cholerae O1 strains were also determined. Significant elevations in the homologous antibody response were found only in the convalescent-phase sera from both groups of patients with cholera. These findings may explain the basis for the lack of heterologous protection between the two serogroups of V. cholerae. Healthy controls had higher background levels of vibriocidal antibody to V. cholerae O1 than to V. cholerae O139.
Similar articles
-
Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.Infect Immun. 1997 Sep;65(9):3571-6. doi: 10.1128/iai.65.9.3571-3576.1997. Infect Immun. 1997. PMID: 9284121 Free PMC article.
-
Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.Clin Diagn Lab Immunol. 1997 May;4(3):264-9. doi: 10.1128/cdli.4.3.264-269.1997. Clin Diagn Lab Immunol. 1997. PMID: 9144361 Free PMC article.
-
Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.Vaccine. 2009 Feb 25;27(9):1386-92. doi: 10.1016/j.vaccine.2008.12.041. Epub 2009 Jan 13. Vaccine. 2009. PMID: 19146897
-
Epidemiology & molecular biology of Vibrio cholerae O139 Bengal.Indian J Med Res. 1996 Jul;104:14-27. Indian J Med Res. 1996. PMID: 8783504 Review.
-
Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype.J Infect Dis. 1994 Aug;170(2):278-83. doi: 10.1093/infdis/170.2.278. J Infect Dis. 1994. PMID: 8035010 Review.
Cited by
-
Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera.Am J Trop Med Hyg. 2014 May;90(5):873-81. doi: 10.4269/ajtmh.13-0498. Epub 2014 Mar 31. Am J Trop Med Hyg. 2014. PMID: 24686738 Free PMC article.
-
A Self-Assembling Whole-Cell Vaccine Antigen Presentation Platform.J Bacteriol. 2018 Jul 10;200(15):e00752-17. doi: 10.1128/JB.00752-17. Print 2018 Aug 1. J Bacteriol. 2018. PMID: 29483163 Free PMC article.
-
Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.mSphere. 2018 Jun 6;3(3):e00245-18. doi: 10.1128/mSphere.00245-18. Print 2018 Jun 27. mSphere. 2018. PMID: 29875145 Free PMC article.
-
A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.Vaccine. 2018 Jul 5;36(29):4317-4324. doi: 10.1016/j.vaccine.2018.05.102. Epub 2018 Jun 9. Vaccine. 2018. PMID: 29895500 Free PMC article. Clinical Trial.
-
Seroconversion and Kinetics of Vibriocidal Antibodies during the First 90 Days of Re-Vaccination with Oral Cholera Vaccine in an Endemic Population.Vaccines (Basel). 2024 Apr 8;12(4):390. doi: 10.3390/vaccines12040390. Vaccines (Basel). 2024. PMID: 38675772 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical